Bitcoin ETF Approval: Mark Your Calendars For January As SEC Decides Crypto’s Fate

Scott Johnsson, a general partner at Van Buren Capital, is hyping up the "official" date range for when regulators will approve Spot Bitcoin Exchange-Traded Funds (ETFs).

Scott Johnsson, a general partner at Van Buren Capital, is hyping up the “official” date range for when regulators will approve Spot Bitcoin Exchange-Traded Funds (ETFs).

What Happened: Johnsson, citing a letter from Sherry Haywood of the U.S. Securities and Exchange Commission, expects approval to take place sometime between Jan. 5 and Jan. 10, 2024.

His comment echoes previous statements from Bloomberg analyst Eric Balchunas who, on Nov. 29, said there is a 90% probability of a Bitcoin ETF approval by Jan. 10.

Also Read: Starknet’s Treasure Chest Unlocks: Provisions Portal Leak Reveals Token Distribution Plans

Why It Matters: The pending decision represents a significant milestone in the cryptocurrency sector as it could pave the way for greater mainstream adoption and investment in Bitcoin and other digital assets.

The SEC is currently reviewing applications from various firms including BlackRock (NYSE:BLK), Grayscale, 21Shares & Ark, Bitwise, VanEck, Wisdomtree, Invesco & Galaxy, Fidelity, and Valkyrie. However, there is a possibility of further delays.

On Friday, Bitcoin’s value soared, reaching approximately $39,000, marking its highest level since May 2022.

Despite regulatory pressures in the cryptocurrency sector, including Binance‘s (CRYPTO: BNB) recent $4.3 billion settlement, the digital currency achieved notable gains.

In the week of Thanksgiving, Bitcoin’s value increased by roughly 5%, and it’s projected to rise close to 3% in the current week.

Read Next: Colombia Looks To Transform Into A Blockchain Haven: President Gustavo Petro Paves The Way For Tech Supremacy

Total
0
Shares
Related Posts
Read More

Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy’s Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M

The deal covers the U.S., Canada, European Union, Great Britain, And Israel. Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating

ATXI